What is the expected price of Encidipine if it is included in medical insurance?

Ensidipine, whose English name is Enasidenib, is a specific drug for patients with acute myeloid leukemia (AML) who have mutations in isocitrate dehydrogenase 2 (IDH2). AML, a malignant tumor that affects the white blood cells in the bone marrow, often causing the bone marrow to malfunction and overproduce abnormal white blood cells. In some AML cases, common IDH2 mutations disrupt the normal metabolism of cells, thereby fueling the growth of cancer cells. By inhibiting this mutated IDH2 enzyme, ensidipine helps restore normal cell metabolism and effectively curbs the progression of cancer.

After a series of rigorous clinical trials, the therapeutic effect of ensidipine on AML patients with IDH2 mutations has been clearly verified. Data show that patients treated with this drug have significantly improved their condition and prolonged their survival. Although this drug may be associated with mild discomfort such as nausea, vomiting, and diarrhea, these are normal drug reactions. In addition, you also need to be alert to a serious side effect called differentiation syndrome, which is inflammation caused by the rapid differentiation of cancer cells and requires prompt medical treatment.

However, unfortunately, although ensidipine has been widely recognized for its efficacy, as of now, it has not been officially launched in mainland China, nor has it been included in the medical insurance catalog. This means that domestic patients cannot purchase this drug through conventional channels, nor can they enjoy the reimbursement policy of medical insurance.

In foreign countries, especially in Laos and Bangladesh, there are already some relatively affordable generic drugs of ensidipine. These generic drugs are similar in efficacy to the original drugs, but at a much lower price, providing an economical treatment option for many patients. This also makes us full of expectations for the future domestic medical insurance reimbursement price of ensidipine.

In general, ensidipine, as a targeted therapeutic drug, brings new treatment hope to specificAML patients. Although it is not currently on the market in China and is not included in medical insurance, once these problems are solved, it is expected that its reimbursement price will be very close to the people, bringing good news to more patients.